"there is an issue that needs to be addressed in terms of the narrative the health trust tried to present and mislead the inquest and cover up what actually happened.
.
cambridge's bluebird bio licenses delivery tech to novartis, gsk
.
phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before.
.
.
.